Program
pitolisant
Also written as “Pitolisant”, “Open-label Pitolisant” and “Pitolisant Oral Tablet”.
Its studies are mostly in Prader-Willi Syndrome · Idiopathic Hypersomnia · Myotonic Dystrophy · Disorders of Excessive Somnolence · Diabetes Mellitus, Type 1, led by 3 companies.
Drug pagePitolisant: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Harmony Biosciencesits history only | 62 open or running | phase 3since Dec 1, 2021 | Jan 29, 2020 | Apr 2027phase 3 · NCT06366464 |
| Citrine Medicineits history only | 10 open or running | phase 3since Jan 24, 2022 | Jan 24, 2022 | none ahead |
| High Point Clinical Trials Center | 10 open or running | phase 1since Jul 17, 2019 | Jul 17, 2019 | none ahead |
Also a collaborator on its studies: Ferox Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of High Point Clinical Trials Center only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 17, 2019First study: phase 1 study in Diabetes Mellitus, Type 1First studyNCT04026750 · 5 enrolled · United States
TargetBeta
“Histamine H3 receptor inverse agonist; Histamine H3 receptor inverse agonist”ChEMBL 37, by rule
Other programs on HRH3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| samelisantrule | suven-life-sciences-limited | phase 3 | 3 |
Studies
The one study High Point Clinical Trials Center leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04026750Diabetes Mellitus, Type 1 · United States | 1 | Terminated | Feb 16, 2020 | 5 |
How it is read
Names in the registry
- “Pitolisant”, 4 entries
- “Open-label Pitolisant”, 1 entry
- “Pitolisant Oral Tablet”, 1 entry
- “Pitolisant tablet”, 1 entry
- “Pitolisant oral tablets”, 1 entry
Conditions, from the studies’ own filings
- Prader-Willi Syndrome, 3 studies
- Idiopathic Hypersomnia, 2 studies
- Myotonic Dystrophy, 1 study
- Disorders of Excessive Somnolence, 1 study
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.